Antineoplastic treatment with crizotinib during pregnancy: a case report
Publikation: Bidrag til tidsskrift › Letter › Forskning › fagfællebedømt
Dokumenter
- Fulltext
Forlagets udgivne version, 959 KB, PDF-dokument
The rare concurrence of pregnancy and lung cancer presents a significant clinical challenge. In younger patients, the presence of molecular driver mutations is more frequently observed [Citation1], but treatment experience with newer targeted therapies during pregnancy is extremely limited. Here, we present a patient who was diagnosed with anaplastic lymphoma kinase (ALK) rearranged non-small cell lung cancer (NSCLC) and received treatment with the ALK inhibitor crizotinib during pregnancy.
Originalsprog | Engelsk |
---|---|
Tidsskrift | Acta Oncologica |
Vol/bind | 58 |
Udgave nummer | 1 |
Sider (fra-til) | 121-122 |
Antal sider | 2 |
ISSN | 0284-186X |
DOI | |
Status | Udgivet - 2019 |
ID: 357333047